Scopus BioPharma Inc. (SCPS)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2022 | -124.57 Thousand USD | 98.43% |
| 2021 | -7.94 Million USD | -1858.73% |
| 2020 | 451.63 Thousand USD | 1329.03% |
| 2019 | -36.74 Thousand USD | -2113.67% |
| 2018 | -1660.00 USD | 98.95% |
| 2017 | -158.21 Thousand USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 Q2 | -362.09 Thousand USD | 74.16% |
| 2023 Q1 | -1.4 Million USD | -1025.01% |
| 2022 Q2 | -1.15 Million USD | 70.91% |
| 2022 FY | -124.57 Thousand USD | 98.43% |
| 2022 Q3 | -310.82 Thousand USD | 73.12% |
| 2022 Q4 | -124.57 Thousand USD | 59.92% |
| 2022 Q1 | -3.97 Million USD | 49.96% |
| 2021 Q3 | -3.63 Million USD | -5.04% |
| 2021 FY | -7.94 Million USD | -1858.73% |
| 2021 Q2 | -3.45 Million USD | 39.47% |
| 2021 Q1 | -5.71 Million USD | -1364.81% |
| 2021 Q4 | -7.94 Million USD | -118.69% |
| 2020 FY | 451.63 Thousand USD | 1329.03% |
| 2020 Q4 | 451.63 Thousand USD | -71.83% |
| 2020 Q3 | 1.6 Million USD | 0.0% |
| 2019 Q4 | -36.74 Thousand USD | 0.0% |
| 2019 FY | -36.74 Thousand USD | -2113.67% |
| 2019 Q1 | -546.48 Thousand USD | 0.0% |
| 2019 Q2 | -869.42 Thousand USD | -59.09% |
| 2018 FY | -1660.00 USD | 98.95% |
| 2017 FY | -158.21 Thousand USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| America Great Health | 1.81 Million USD | 106.859% |
| Ampio Pharmaceuticals, Inc. | -3.81 Million USD | 96.735% |
| Aridis Pharmaceuticals, Inc. | 1.25 Million USD | 109.934% |
| Biora Therapeutics, Inc. | 32.21 Million USD | 100.387% |
| Bio-Path Holdings, Inc. | -939 Thousand USD | 86.733% |
| Better Therapeutics, Inc. | -860 Thousand USD | 85.515% |
| Calithera Biosciences, Inc. | -23.78 Million USD | 99.476% |
| Comera Life Sciences Holdings, Inc. | 328.44 Thousand USD | 137.929% |
| Gene Biotherapeutics, Inc. | - USD | Infinity% |
| eFFECTOR Therapeutics, Inc. | 4.57 Million USD | 102.726% |
| Eloxx Pharmaceuticals, Inc. | -5.82 Million USD | 97.861% |
| Evelo Biosciences, Inc. | 3.19 Million USD | 103.895% |
| Evolutionary Genomics, Inc. | 3.16 Million USD | 103.934% |
| Finch Therapeutics Group, Inc. | 5 Million USD | 102.491% |
| Galera Therapeutics, Inc. | 134.04 Million USD | 100.093% |
| Innovation1 Biotech Inc. | 179.15 Thousand USD | 169.537% |
| Kiromic BioPharma, Inc. | 12.33 Million USD | 101.01% |
| Molecular Templates, Inc. | 707 Thousand USD | 117.62% |
| Navidea Biopharmaceuticals, Inc. | 438.44 Thousand USD | 128.413% |
| NexImmune, Inc. | -3.13 Million USD | 96.025% |
| Orgenesis Inc. | 21.78 Million USD | 100.572% |
| Panbela Therapeutics, Inc. | 2.61 Million USD | 104.762% |
| Point of Care Nano-Technology, Inc. | -498.00 USD | -24915.06% |
| PaxMedica, Inc. Common Stock | -4.71 Million USD | 97.355% |
| Sorrento Therapeutics, Inc. | 110.87 Million USD | 100.112% |
| Statera Biopharma, Inc. | 14.41 Million USD | 100.864% |
| TRACON Pharmaceuticals, Inc. | -7.59 Million USD | 98.36% |
| Trevena, Inc. | 2.25 Million USD | 105.517% |
| Vaxxinity, Inc. | 10.13 Million USD | 101.23% |
| Vaccinex, Inc. | -1.28 Million USD | 90.328% |
| Vicapsys Life Sciences, Inc. | 344.44 Thousand USD | 136.167% |
| Viracta Therapeutics, Inc. | 13.23 Million USD | 100.941% |
| ZIVO Bioscience, Inc. | 71.96 Thousand USD | 273.112% |